Executive Briefing
Week ending September 27, 2026
1. Headline
16 inconsistency flags this week, down 4 week over week, but clinically important answer variability persists. Hypoglycemia mentions rose to 29 (+5) and pancreatitis to 29 (+2), while competitor visibility rebounded modestly, led by Wegovy (11, +2). The immediate priority is tightening consistency around contraindications and serious safety warnings—not expanding promotional claims.
2. This week at a glance
| Metric | This week | Change |
|---|---|---|
| Distinct questions / responses | 10 / 65 | +1 / +2 |
| Cross-response inconsistency flags | 16 | -4 |
| Top competitor mentions | Wegovy 11; Trulicity 2; Mounjaro 2 | +2; +2; +2 |
| Top safety/regulatory themes | Pancreatitis 29; hypoglycemia 29; contraindication 27 | +2; +5; -7 |
Model attribution is not used here because a reliable model-identity flag was not provided; _llm_label values are treated as response variants.
3. Trajectory
Safety consistency is improving from the August peak: inconsistency flags fell from 39 on August 9 to 22 on September 6, 18 on September 13, 20 on September 20, and 16 this week. The recent improvement is meaningful, although 16 flags still indicate material answer-level variability.
Monitoring volume has also contracted sharply from 120–140 responses weekly in late July/August to approximately 63–65 over the past two weeks, so raw theme counts should be interpreted cautiously. Within the recent period, hypoglycemia has increased (24 → 29) while contraindication mentions have declined (34 → 27).
Competitor visibility is not on a sustained upward trend: Wegovy mentions fell from 47 at the July 26 peak to 9 last week, then rose to 11. However, Trulicity and Mounjaro reappeared this week, suggesting broader comparative questioning.
4. Where the risk actually is
- Warnings question: In 7 answers, six mentioned allergic reactions, contraindications, and kidney injury; one omitted each. A patient could therefore receive materially different safety guidance to the same warning-focused question.
- “Who should not take Ozempic?” Hypoglycemia was omitted in one of seven answers, while kidney-related caution appeared in only two. The core contraindications are generally present, but surrounding safety context is inconsistent.
- Pancreatitis management: Six of seven answers framed contraindication-related action, while one did not. Most answers advise stopping Ozempic and urgent evaluation, but inconsistent wording (“stop next dose” versus “stop immediately”) creates avoidable ambiguity.
5. Recommended actions
- Medical Affairs/Regulatory: Create a concise, approved safety-answer framework covering MTC/MEN2, hypersensitivity, pancreatitis, hypoglycemia, renal monitoring, and pregnancy; target the 16 inconsistency flags.
- Content/SEO: Build FAQ content for the three highest-variability questions, with explicit “do not use,” “hold/stop,” and urgent-evaluation language.
- PV/Medical Information: Review pancreatitis, pregnancy, and renal wording for clinical precision and escalation instructions.
- Marketing/Compliance: Audit comparative and weight-loss responses; Wegovy appears in 11 answers, while Trulicity and Mounjaro each appear in 2, requiring label-aligned comparison guardrails.